SMARCB1 and chordoma: Agents targeting EZH2 have shown to induce tumor regression and promote radiation sensitivity in models of SMARCB1/INI1-deficient tumors, including poorly differentiated chordomas, malignant rhabdoid tumors and epithelioid sarcomas (4, 10, 11).